At week @ , significantly more subjects receiving ETN + MTX vs subjects on csDMARDs + MTX achieved DAS@-ESR LDA ( @ % vs @ % , P < @ ) , remission ( @ % vs @ % , P < @ ) and HAQ @ ( @ % vs @ % , P < @ ) .